Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002295 · ClinicalTrials.gov registry record · NA

A Study of Isoprinosine in Patients With Severe AIDS

A NA study of HIV Infections, sponsored by Newport Pharmaceuticals International.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002295: Completed NA study of HIV Infections, sponsored by Newport Pharmaceuticals International.

NCT00002295 is a NA study of HIV Infections that has completed, run by Newport Pharmaceuticals International. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002295, a NA study of HIV Infections, has completed, sponsored by Newport Pharmaceuticals International.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to: Laboratory (immunologic defects): * Comparison of total helper and suppressor T-cell numbers among the groups. * Comparison of changes in natural killer cell activity. * Comparison of other laboratory findings among the groups. Clinical changes: * Comparison of the frequency of opportunistic infections among the groups. * Comparison of the frequency of the development of AIDS-related malignancies. * Comparison of other clinical manifestations relative to severity and time of onset.

Conditions Studied

HIV Infections

Interventions

  • DRUG Inosine pranobex

Study Locations (1)

California

  • Newport Pharmaceuticals International Inc - Laguna Hills

Trial Details

FieldValue
Phase NA
Newport Pharmaceuticals International

6 total trials

What the finished NCT00002295 record still lists

NCT00002295 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Inosine pranobex is the first listed.

NCT00002295 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00002295 about?

NCT00002295 is a clinical study titled "A Study of Isoprinosine in Patients With Severe AIDS". To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to: Laboratory (immunologic defects): * Comparison of total helper and suppressor T-cell numbers among the groups. * Comparison of changes in natural killer cell activity. * Comparison of other laboratory findings...

What is the current status of trial NCT00002295?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002295 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002295?

The interventions under investigation include: Inosine pranobex (DRUG).

Who is sponsoring clinical trial NCT00002295?

This trial is sponsored by Newport Pharmaceuticals International, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002295 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002295, the US trial registry maintained by the National Library of Medicine. NCT00002295 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.